MYSTIC, Conn. and DUBLIN, Jan. 7, 2011 /PRNewswire/ — Amarin
Corporation plc (Nasdaq:
AMRN) (the “Company”), a clinical-stage biopharmaceutical
company with a focus on cardiovascular disease, today announced
that, in connection with its previously announced underwritten
public offering of American Depositary Shares (“ADSs”), the
underwriters of the offering have exercised in full their option to
purchase up to an aggregate of 1,800,000 additional ADSs to cover
over-allotments. The exercise of the over-allotment option
increases the size of the offering to an aggregate of 13,800,000
ADSs at a public offering price of $7.60 per ADS. Amarin expects to
receive from the offering net proceeds of approximately $100.2
million, after deducting underwriting discounts and commissions and
other estimated offering expenses. The offering, including the
purchase of the additional ADSs, is expected to close on or about
January 11, 2011, subject to customary closing conditions.
Jefferies & Company, Inc. and Leerink Swann LLC are acting
as joint book-running managers in the offering, and Canaccord
Genuity Inc. is acting as co-lead manager for the offering. Amarin
anticipates using the net proceeds from the offering to prepare for
the commercialization of AMR101, its filing of a New Drug
Application and for working capital and general corporate
purposes.
The securities described above are being offered by Amarin
pursuant to a shelf registration statement previously filed with
and declared effective by the Securities and Exchange Commission
(the “SEC”) on November 23, 2010. Copies of the base prospectus,
preliminary prospectus supplement and related prospectuses relating
to these securities may be obtained from Equity Syndicate
Prospectus Department, Jefferies & Company, Inc., 520 Madison
Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340, and at
